Evidence map›Paper›PMID 34820520›Full record

ArticleClinical mass spectrometry (Del Mar, Calif.)2020

Direct detection of intact

William M McGee, Matthew L Faron, Jason R Neil, Scott R Kronewitter, Blake W Buchan, Nathan A Ledeboer, James L Stephenson

Open access · greenAbstract read
In one paragraph

Article in Clinical mass spectrometry (Del Mar, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

William M McGeeThermo Fisher Scientific, Cambridge, MA, United States.
Matthew L FaronMedical College of Wisconsin, Milwaukee, WI, United States.
Jason R NeilThermo Fisher Scientific, Cambridge, MA, United States.
Scott R KronewitterThermo Fisher Scientific, Cambridge, MA, United States.
Blake W BuchanMedical College of Wisconsin, Milwaukee, WI, United States.
Nathan A LedeboerMedical College of Wisconsin, Milwaukee, WI, United States.
James L StephensonThermo Fisher Scientific, Cambridge, MA, United States.
Thermo Fisher Scientific (United States) · USMedical College of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCarbapenemase-producing organisms (CPOs) are a growing threat to human health. Among the enzymes conferring antibiotic resistance produced by these organisms,

objectivesThe objective of this study is to develop an intact protein mass spectrometry-based method for detection and differentiation of clinically-relevant KPC variants directly from bacterial cell lysates. The method should be specific for any variant expressed in multiple bacterial species, limit false positive results and be rapid in nature to directly influence clinical outcomes.

methodsLysates obtained directly from bacterial colonies were used for intact protein detection using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Bottom-up and top-down proteomic methods were used to characterize the KPC protein targets of interest. Comparisons between KPC-producing and KPC-non-producing isolates from a wide variety of species were also performed.

resultsCharacterization of the mature KPC protein revealed an unexpected signal peptide cleavage site preceding an AXA signal peptide motif, modifying the molecular weight (MW) of the mature protein. Taking the additional AXA residues into account allowed for direct detection of the intact protein using top-down proteomic methods. Further validation was performed by transforming a KPC-harboring plasmid into a negative control strain, followed by MS detection of the KPC variant from the transformed cell line. Application of this approach to clearly identify clinically-relevant variants among several species is presented for KPC-2, KPC-3, KPC-4 and KPC-5.

conclusionDirect detection of these enzymes contributes to the understanding of occurrence and spread of these antibiotic-resistant organisms. The ability to detect intact KPC variants via a simple LC-MS/MS approach could have a direct and positive impact on clinical therapy, by providing both direction for epidemiological tracking and appropriate therapy.

Indexed as

ATCC, American type culture collectionBLAST, basic local alignment search toolCarbapenemase-producing organismsCarbapenem-resistant EnterobacteriaceaeCDC, Centers for Disease Control and PreventionCPO, carbapenemase-producing organismsCSD, charge state distributionESI, electrospray ionizationKlebsiella pneumoniae carbapenemaseKPC, Klebsiella pneumoniae carbapenemaseLC, liquid chromatographyMALDI, matrix-assisted laser desorption ionizationMass SpectrometryMS, mass spectrometryMS/MS, tandem mass spectrometryMW, molecular weightm/z, mass-to-charge ratioPCR, polymerase chain reactionTandem mass spectrometryTOF, time-of-flight

Identifiers

PMID34820520
PMCPMC8600995
OpenAlexW3042808414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.